EC set to strip cranberry products of medical device status


- Last updated on GMT

© iStock
© iStock

Related tags Medical devices European union Urinary tract infection

The European Commission (EC) has issued a draft that seeks to revoke the medical device status of proanthocyanidin (PAC)-based cranberry products for treatment and prevention of Urinary Tract Infections (UTI). 

The draft specifies PAC-based medical devices and notes that French authorities which stripped​ French player Arkopharma of its medical devices status in 2014 for a lack of data, made the demand to the EC to similarly remove all PAC-based cranberry medical devices across the 28-nation EU bloc.

The EC move was welcomed by Gunter Haesaerts, the president of French cranberry supplements manufacturer, Pharmatoka, and long-time critic of the medical devices route being pursued by supplements making stronger claims than those rejected under the strict EU nutrition and health claims regulation (NHCR) since 2008.

All cranberry claims have been rejected by the European Food Safety Authority (EFSA) under the NHCR, a situation that provoked the likes of Arkopharma to pursue the medical devices route a few years ago. Dutch firm Medical Brands was another that launched cranberry medical devices products around then after several years of research and development. 

The shift raised concerns among many EU MEPs and so the medical devices directive is set for revision this year and the sector expects its products will require a higher level of scientific backing under class III of the reformed directive.

cranberry infection fruit berry
© iStock

Medical Brands marketing strategy manager Victoria Fedorova told u​that actions related to Article 13 of the medical devices directive are based on the draft definition of pharmacological mode of action, which is yet to be finalised.

If the draft is approved, PAC-based cranberry medical devices will disappear from the market and cranberry medical device manufacturers will have to decide whether to reclassify them as medicinal products, or develop non-PAC based medical devices. Medical Brands says the proprietary science backing its class IIb cranberry-UTI products is not PAC-based, rather based on other cranberry compounds.

Fedorova said the draft was not yet implemented and may be influenced by parallel discussions occurring at EU level with regards to Rule 21 of the reformed directive and yet to be agreed definitions of metabolic, physiological and pharmacological mode of actions.

Rule 21

Rule 21 defines what a substance-based medical device can be. It has been the hottest point of contention in medical device revision discussions and highlighted the difficulty in classifying a range of products as broad as nasal sprays, eye drops, topical creams and traditional pills and food supplements.

There are several categories of risk within the medical devices legislation, and it is likely the amendments as they stand would push many products to a higher risk classification meaning that class I and class II substance-based medical devices may cease to exist as they will all have to meet class III requirements

There will be a 5-year transition once the revised directive goes live although John Wilkinson, director of medical devices at the UK MHRA (Medicines and Healthcare products Regulatory Authority), has noted​ many applications would address the regulation immediately once it entered EU lawbooks.

Related news

Show more

Related products

show more

Optimize Nutritional Value with DuraLipo™

Optimize Nutritional Value with DuraLipo™

Content provided by INNOBIO Corporation Limited | 02-May-2024 | White Paper

INNOBIO's DuraLipo™ products encapsulates active ingredients within phospholipids, forming a genuine phospholipid bilayer structure.

Women's Health Before, During & Beyond Menopause

Women's Health Before, During & Beyond Menopause

Content provided by Akay Bioactives | 26-Apr-2024 | White Paper

Discover the science of FenuSmart®, a unique fenugreek seed extract that merges ancient wisdom with modern clinical research to support women's health...

Related suppliers

1 comment

Lobbyism at work!

Posted by Oliver Schulz,

NO one is hurt by Cranberry extracts being marketed as medical devices.
Many people with UIT profit enormously.
A safe alternative to costly medication is destroyed - for the better of the pharmaceutical industry's profits - at the cost of the people.
Why? Cherchez la lobby!!!

Report abuse

Follow us


View more